[Current aspects in the therapy of renal cell cancer].
The nephron-sparing partial nephrectomy has become the gold standard in the surgical therapy of small renal tumors (4-7 cm). In metastased renal cell cancers it is reasonable to perform a nephrectomy or a partial nephrectomy in combination with cytokine-therapy (clear cell type) and/or a targeted therapy with Angiogenesis-Inhibition, in presence of a Karnofsky-Index > 70%. A surgical standard procedure for organ-confined renal cell cancers and an immunological standard therapy for metastased renal cell cancers are no more proper; in fact nowadays exists a spectrum of different efficient therapies. Surgery in metastased diseases is indicated if it can improve the quality of life of the patient.
Heynemann
H
H
Univ.-Klinik und Poliklinik für Urologie, Klinikum Medizinischen Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle. hans.heynemann@medizin.uni-halle.de
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D016207:Cytokines / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D010535:Laparoscopy; D009367:Neoplasm Staging; D009392:Nephrectomy / Q000379:methods*; D011379:Prognosis; D011788:Quality of Life
D016207:Cytokines